Conjugate vaccines for preventing meningococcal C meningitis and septicaemia

Conterno, Lucieni de Oliveira; Filho, Carlos Rodrigues da Silva; Rüggeberg, Jens U.; Heath, Paul T

doi:10.1002/14651858.cd001834.pub2

Cited by 14 publications

(11 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A massive catch-up campaign targeted all children and young adults from 2 months to 18 years (later extended to 24 years) of age. As part of the simultaneous introduction of MenC vaccine into However, additional postlicensure surveillance revealed that despite short-term immunogenicity in all age groups [7], MenC vaccine effectiveness wanes rapidly in children !3 years of age [3] and is associated with a reduction in the proportion of children with a serum bactericidal antibody (SBA) titer above the accepted correlate of protection (serological protection). Persistence of an adequate postimmunization SBA titer rather than the demonstration of an anamnestic response to subsequent antigen challenge is now regarded as the key to the maintenance of individual protection against the rapid invasion of MenC [8].…”

mentioning

confidence: 99%

Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical Trial

et al. 2010

View full text Add to dashboard Cite

As a result of waning antibody, the majority of 6-12-year-old children in the United Kingdom have inadequate serological protection against MenC. The persistence of MenC immunity and the response to a Hib-MenC booster is dependent on age at priming. A booster was highly effective in this cohort and could sustain population immunity against MenC disease. Trial registration. Current Controlled Trials ( http://www.controlled-trials.com ) identifier: ISRCTN72858898 .

show abstract

mentioning

confidence: 99%

Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical Trial

et al. 2010

View full text Add to dashboard Cite

show abstract

“…A systematic review of RCTs found the serogroup A vaccine to be 95% (95% CI, 89%–99%) effective against meningococcal A meningitis for the first year in the general population ( 133 ). A systematic review of observational studies found meningococcal serogroup C vaccines to be highly immunogenic for preventing meningococcal C meningitis and septicemia ( 134 ). Routine immunization programs have led to dramatic reductions in the incidence of meningococcal serogroup C disease ( 134 ).…”

Section: Inactivated Vaccines In Patients With Inflammatory Bowel Diseasementioning

confidence: 99%

“…A systematic review of observational studies found meningococcal serogroup C vaccines to be highly immunogenic for preventing meningococcal C meningitis and septicemia ( 134 ). Routine immunization programs have led to dramatic reductions in the incidence of meningococcal serogroup C disease ( 134 ).…”

Section: Inactivated Vaccines In Patients With Inflammatory Bowel Diseasementioning

confidence: 99%

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines

Jones

Tse

Carroll

et al. 2021

Journal of the Canadian Association of Gastroenterology

View full text Add to dashboard Cite

Background and Aims The effectiveness and safety of vaccinations can be altered by immunosuppressive therapies, and perhaps by inflammatory bowel disease (IBD) itself. These recommendations developed by the Canadian Association of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide guidance on immunizations in adult and pediatric patients with IBD. This publication focused on inactivated vaccines. Methods Systematic reviews evaluating the efficacy, effectiveness, and safety of vaccines in patients with IBD, other immune-mediated inflammatory diseases, and the general population were performed. Critical outcomes included mortality, vaccine-preventable diseases, and serious adverse events. Immunogenicity was considered a surrogate outcome for vaccine efficacy. Certainty of evidence and strength of recommendations were rated according to the GRADE (Grading of Recommendation Assessment, Development, and Evaluation) approach. Key questions were developed through an iterative online platform, and voted on by a multidisciplinary group. Recommendations were formulated using the Evidence-to-Decision framework. Strong recommendation means that most patients should receive the recommended course of action, whereas a conditional recommendation means that different choices will be appropriate for different patients. Results Consensus was reached on 15 of 20 questions. Recommendations address the following vaccines: Haemophilus influenzae type b, recombinant zoster, hepatitis B, influenza, pneumococcus, meningococcus, tetanus-diphtheria-pertussis, and human papillomavirus. Most of the recommendations for patients with IBD are congruent with the current Centers for Disease Control and Prevention and Canada’s National Advisory Committee on Immunization recommendations for the general population, with the following exceptions. In patients with IBD, the panel suggested Haemophilus influenzae type b vaccine for patients older than 5 years of age, recombinant zoster vaccine for adults younger than 50 year of age, and hepatitis B vaccine for adults without a risk factor. Consensus was not reached, and recommendations were not made for 5 statements, due largely to lack of evidence, including double-dose hepatitis B vaccine, timing of influenza immunization in patients on biologics, pneumococcal and meningococcal vaccines in adult patients without risk factors, and human papillomavirus vaccine in patients aged 27–45 years. Conclusions Patients with IBD may be at increased risk of some vaccine-preventable diseases. Therefore, maintaining appropriate vaccination status in these patients is critical to optimize patient outcomes. In general, IBD is not a contraindication to the use of inactivated vaccines, but immunosuppressive therapy may reduce vaccine responses.

show abstract

“…WHO also recommends that national childhood immunization programs include the conjugate vaccine against Neisseria meningitides . Meningococcus is a bacteria associated with a high rate of morbidity and mortality due to the sudden onset and rapid progression of infection, particularly in adolescent populations [ 43 ]. Multiple meningococcal immunizations exist.…”

Section: Immunizationsmentioning

confidence: 99%

Prevention of Sepsis in Children: A New Paradigm for Public Policy

Riley

Wheeler

2012

Critical Care Research and Practice

View full text Add to dashboard Cite

Sepsis is one of the leading causes of death worldwide. While the management of critically ill patients with sepsis is certainly better now compared to 20 years ago, sepsis-associated mortality remains unacceptably high. Annual deaths from sepsis in both children and adults far surpass the number of deaths from acute myocardial infarction (AMI), stroke, or cancer. Given the substantial toll that sepsis takes worldwide, prevention of sepsis remains a global priority. Multiple effective prevention strategies exist. Antibiotic prophylaxis, immunizations, and healthcare quality improvement initiatives are important means through which we may reduce the morbidity and mortality from sepsis around the world. Inclusion of these strategies in a coordinated and thoughtful campaign to reduce the global burden of sepsis is necessary for the improvement of pediatric health worldwide.

show abstract

Conjugate vaccines for preventing meningococcal C meningitis and septicaemia

Cited by 14 publications

References 65 publications

Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical Trial

Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical Trial

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines

Prevention of Sepsis in Children: A New Paradigm for Public Policy

Contact Info

Product

Resources

About